Novel Intravaginal Ring as a Non-Hormonal Contraceptive Multipurpose Prevention Technology (MPT)
The Population Council and partners are advancing the development of a non-hormonal vaginal ring with potential to provide contraception along with broad microbial action against bacterial vaginosis-associated bacteria, HIV, HSV-2, chlamydia, and gonorrhea. This ring will also be designed with the added benefit of promoting vaginal health by helping to maintain optimal vaginal pH and reducing symptoms of bacterial vaginosis.
Development Stage:
Pre-formulation, pre-Phase 1 Clinical Trials among end-users, Non-clinical
Hormonal/Non-Hormonal:
Non-Hormonal
Delivery Route & Method:
Intravaginal - Intravaginal Ring (IVR)
Mechanism of Action:
These actives will have spermicidal activity and broad antibacterial/antiviral activity against chlamydia, gonorrhea, bacterial vaginosis, HSV-2, and HIV. The ring will also increase vaginal lactic acid concentrations that could further optimize vaginal health, providing a significant secondary benefit of reducing symptoms of bacterial vaginosis (BV).
Developer:
- Population Council
- Queen's University Belfast
- Weill Cornell Medical College
Funding:
- National Institutes of Health (NIH)
- Nat. Institute Child Health & Human Development (NICHD)
Funding Mechanism:
P50 Clinical Research Center Grant
Past Funding:
N/A
Active Ingredient(s):
- Copper
- Zinc
- Lactide
Product Indication(s):
- Bacterial Vaginosis (BV)
- Chlamydia
- Gonorrhea
- HIV
- HSV-2
- Pregnancy